Current Report Filing (8-k)
November 30 2021 - 4:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): November 23, 2021
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-54318
|
|
98-0573252
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS Employer
Identification No.)
|
24
North Main Street
Pennington,
NJ 08534-2218
(Address
of Principal Executive Offices)
(855)
662-6732
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
ONCS
|
|
NASDAQ
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02.
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
On
November 23, 2021, Robert E. Ward, notified OncoSec Medical Incorporated (the “Company”) of his resignation from the Board
of Directors (the “Board”), effective immediately. Concurrently with such resignation, Mr. Ward ceased to serve as Chair
of the Audit Committee. Mr. Ward’s resignation from the Board was not the result of any disagreement with the Company on any matter
related to the Company’s operations, policies or practices, the Company’s management or the Board.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ONCOSEC
MEDICAL INCORPORATED
|
|
(Registrant)
|
|
|
|
Date:
November 30, 2021
|
|
|
|
|
|
|
By:
|
/s/
Dr. Margaret Dalesandro
|
|
Name:
|
Dr.
Margaret Dalesandro
|
|
Title:
|
Interim
Principal Executive Officer and Chair of the Board
|
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2024 to May 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From May 2023 to May 2024